Is tripeptide-10 citrulline FDA-approved, and what does the research show?

What is tripeptide-10 citrulline?

Tripeptide-10 citrulline is a cosmetic ingredient, not an FDA-approved drug ¹,². It is a synthetic peptide: a short chain of amino acids, the building blocks of proteins, made in a laboratory ¹. A 2008 paper describes it as "a new cosmetic active" ¹. Despite the "tripeptide" in its name, that paper calls it a tetrapeptide, a chain of four amino acids ¹. Lubrizol sells it as Decorinyl, a blend of water, lecithin, tripeptide-10 citrulline and other ingredients ⁵.

Its designers modeled it on decorin, a protein that attaches to collagen, the fiber-forming protein of the skin ¹. Acetyl octapeptide-3, another peptide used in cosmetics, has its own page.

Is tripeptide-10 citrulline FDA-approved?

No. Tripeptide-10 citrulline is not FDA-approved as a drug: Drugs@FDA lists no approved tripeptide-10 citrulline product as of November 9, 2026 ². It is a cosmetic ingredient ¹. FDA's page on its authority over cosmetics says, "The law does not require cosmetic products and ingredients, other than color additives, to have FDA approval before they go on the market" ³. So a cosmetic that lists the peptide can go on the market without FDA approval ³.

On who answers for safety, the same page says, "Companies and individuals who manufacture or market cosmetics have a legal responsibility to ensure the safety of their products" ³. It adds that neither the law nor FDA's regulations require specific tests to show that an individual product or ingredient is safe ³.

A 2022 law, the Modernization of Cosmetics Regulation Act (MoCRA), gave FDA new powers over cosmetics, a recall power among them ⁶. FDA says it can order a mandatory recall, if the responsible person will not recall the product voluntarily, once it determines there is "a reasonable probability that a cosmetic is adulterated or misbranded and the use of or exposure to the cosmetic will cause serious adverse health consequences or death" ⁶. The responsible person is the manufacturer, packer or distributor whose name is on the product's label ⁶. FDA's authority page describes adulteration as a violation involving a product's composition, and misbranding as improper labeling or deceptive packaging ³.

FDA's older authority page, written in 2005 and updated in 2013, before MoCRA, still says FDA cannot order recalls; its MoCRA page states the current law ³, ⁶. The older page carries a footer dated March 3, 2005, updated August 3, 2013, and a content date of November 18, 2025 ³.

FDA says the use a product is intended for decides whether the law treats it as a cosmetic or a drug ⁷. As an example of a cosmetic, it gives a product meant to make lines and wrinkles less noticeable only by moisturizing the skin ⁸. A product intended to remove wrinkles, or to raise the skin's production of collagen, is by the same page a drug or a medical device ⁸. The agency also says it is concerned about drug claims made for products sold as cosmetics ⁸. It names skin-care products whose anti-wrinkle or anti-aging claims involve supposed effects on the skin's structure or function ⁸.

See the FDA status of every peptide, updated weekly.

How does tripeptide-10 citrulline work?

The peptide is proposed to work by imitating decorin ¹. The 2008 paper says decorin binds collagen and steers fibrillogenesis, the assembly of collagen into fibers, which limits excessive bundling of the fibers ¹. It says aging skin lacks working decorin, and that collagen fibers are disrupted as a result ¹. The authors started from the two four-amino-acid sequences through which decorin binds collagen, and engineered a set of candidate peptides that mimic them ¹. They screened the candidates in a laboratory test of fiber formation, in which tripeptide-10 citrulline "achieved the best results" ¹.

In the paper's laboratory tests, by its own account, the peptide regulated fiber formation and made collagen fibers "thinner and more uniform" ¹. The paper's abstract, the published summary that is the part cited here, calls the tests "in vitro," a term for work done outside a living body ¹. It does not say what material was tested ¹. used cells, skin samples or purified collagen, and whether the paper reports any test in people, from the full text of ¹; only the PubMed abstract was opened] The authors write that "Skin collagen quality is addressed rather than skin collagen quantity" ¹. They add that the ingredient "increases skin suppleness because of a better cohesion of collagen fibres," without saying in the abstract how suppleness was measured ¹.

These are the statements of a paper whose first author gives the address of Lipotec SA, a company in Spain ¹. Neither abstract cited here reports a test of the peptide reaching collagen in living skin ¹,⁴. In the one human study cited here, the authors wrote that the mechanism by which the two peptides might act together "was not clear in this study" ⁴.

What does the research show?

Studied in people: one randomized controlled study cited here, with 24 participants and with skin-surface texture and water loss as the outcomes ⁴. Researchers in Athens, Greece, assigned 24 healthy volunteers by chance to four groups for 60 days ⁴. One group received tripeptide-10 citrulline, one a different peptide, acetyl hexapeptide-3, one both, and one neither ⁴. The group that received neither is the control, the comparison that makes a study "controlled." The study's title names the two peptides as a combination ⁴.

The team measured skin microtopography, the fine relief of the skin's surface, with an instrument the authors call a skin visioscan ⁴. The abstract reports two parameters from that instrument, cR2 and cR3, without explaining them ⁴. A second instrument measured transepidermal water loss, the water that passes out through the skin ⁴. The abstract does not give each group's size, the number who finished, or the product that carried the peptides ⁴. PubMed's record of that paper indexes acetyl hexapeptide-3 as a chain of six amino acids ⁴.; only the PubMed abstract was opened]

The abstract names the comparisons between groups that were statistically significant, meaning larger than chance alone would readily explain ⁴. It gives each a P value, a measure of how readily chance alone could explain a difference ⁴. Its list of results gives no size or direction for any change ⁴. After 20 days, the tripeptide-10 citrulline group differed from the no-peptide group on one of the two parameters, cR3 (P = .028) ⁴. That group differed from the acetyl hexapeptide-3 group on both parameters (P = .017 each) and from the combination group on both (P = .045 and .044) ⁴.

After 60 days, three comparisons are listed as significant ⁴. The combination group differed from the acetyl hexapeptide-3 group on both parameters (P = .016 and .025) ⁴. The tripeptide-10 citrulline group differed from the acetyl hexapeptide-3 group on both (P = .044 each) ⁴. The combination group differed from the no-peptide group on cR2 (P = .025) ⁴. Tripeptide-10 citrulline alone against no peptide is not on that 60-day list ⁴.

For water loss, the significant differences listed fall after 20 and 40 days, and each involves the acetyl hexapeptide-3 group ⁴. Two are between that group and the tripeptide-10 citrulline group (P = .045 after 20 days and P = .028 after 40) ⁴. None listed is between tripeptide-10 citrulline and no peptide ⁴.

The authors conclude, "We provided clinical evidence for the antiwrinkle efficacy of tripeptide-10 citrulline and possibly TEWL," their abbreviation for transepidermal water loss ⁴. They list affiliations at the Technological Educational Institute of Athens and the University of Athens ⁴.] None of the sources cited here follows users beyond 60 days or tests the peptide in people with a skin condition ¹,⁴.

What are the side effects?

Neither abstract cited here reports side effects, or says whether the researchers looked for any ¹,⁴. The 60-day study enrolled healthy volunteers, and its abstract is silent on skin reactions and on withdrawals ⁴.] So the sources cited here cannot say how often the ingredient irritates skin, or in whom ¹,⁴.

FDA's general rule for cosmetics still applies: "cosmetics must be safe when consumers use them" as the labeling directs or as such products are customarily used ⁸. Under MoCRA, the responsible person must report serious adverse events associated with using a cosmetic product in the United States to FDA within 15 business days ⁶. Serious events, as FDA's page defines them, include inpatient hospitalization, an infection, and serious and persistent rashes ⁶.

In sport

The World Anti-Doping Agency (WADA) publishes the Prohibited List, which sets out the substances and methods prohibited in sport ⁹. Its 2026 list does not name tripeptide-10 citrulline ⁹.

What JumpstartMD offers

JumpstartMD does not prescribe tripeptide-10 citrulline. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.